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Dry solvents were freshly distilled under argon from an appropriate drying agent before use. Gold complexes were 
prepared according to previously reported methods
1,2










 are known compounds and were 
synthesized according to the reported procedures. All other aldehydes used are known compounds
6
 and were 
synthesized according to the reported procedures.
7
 Chiral organocatalyst C1, C2, C3, C4, C8, C 9 and C10 were 










  and C16
12
 are known compounds and were 
synthesized according to the reported procedures. All other reagents used were bought from Aldrich, Alfa Aesar, TCI or 
Acros and used without further purification.  
Reactions were conducted in dry solvents under argon atmosphere unless otherwise stated. The abbreviation “rt” 
refers to reactions carried out approximately at 23 °C. Reaction mixtures were stirred using Teflon-coated magnetic 
stirring bars. Reaction temperatures were maintained using Thermowatch-controlled silicone oil baths. Thin-layer 
chromatography (TLC) was performed on silica gel plates and components were visualized by observation under UV 
light, and / or by treating the plates with p-anisaldehyde or cerium nitrate solutions, followed by heating. Flash 
chromatography was carried out on silica gel unless otherwise stated. Dryings were performed with anhydrous Na2SO4 
or MgSO4. Concentration refers to the removal of volatile solvents via distillation using a Büchi rotary evaporator 
followed by residual solvent removal under high vacuum. NMR spectra were recorded in CDCl3, at 300 MHz (Varian) or 
500 MHz (Varian). Carbon types and structure assignments were determined from DEPT-NMR. NMR spectra were 
analyzed using MestreNova
©
 NMR data processing software (www.mestrelab.com). 1,3,5-Trimethoxybenzene was used 
as internal standard. The following abbreviations are used to indicate signal multiplicity: s, singlet; d, doublet; t, triplet; 
q, quartet; dd, double doublet; ddd, doublet of doublet of doublets; td, triple doublet; dt, doublet of triplets; dq, 
doublet of quartet; m, multiplet; br, broad. Mass spectra (ESI-MS) were acquired using IT-MS Bruker AmaZon SL at 
CIQUS and also using chemical ionization (CI) electron impact (EI), or electrospray ionization (ESI) at the CACTUS facility 
of the University of Santiago de Compostela. The reactions were monitored by TLC. Enantioselectivities were 
determined in an Agilent HPLC 1100 Series with Chiralpak IA, IB, IC, IA3 or OZ-H analytical columns. 
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General procedure for the alkylation of aldehydes with allenamides 
Method A (racemic protocol): 
To a solution of Ph3PAuNTf2 (2:1) toluene adduct (12,55 mg, 0.008 mmol), 2,2’-bipyridine (4.99 mg, 0.032 mmol) and 
benzoic acid (3.90 mg, 0.032 mmol) in Toluene (0.5 ml) in a dried Schlenk tube, was sequentially added a solution of the 
corresponding aldehyde 2 (0.320 mmol) and pyrrolidine (3.97 µl, 0.048 mmol) in Toluene (0.5 ml) and another of the 
corresponding allenamide 1 (0.160 mmol) in Toluene (0.5 ml; dropwise addition). The mixture was stirred under Argon 
atmospher at 60 ºC until the allenamide was consumed (the progress of the reaction was easily monitored by tlc) and 
filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and the crude residue was 
dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl3 for 
1
H-NMR analysis. The crude mixture 
was then purified on column chromatography (hexanes/EtOAc 10-40%). All the reported yields are isolated yields. 
 
Method A´ (racemic protocol followed by in situ reduction with NaBH4): 
Same conditions than Method A but once the allenamide was consumed (the progress of the reaction was easily 
monitored by tlc) the reaction was quenched by the addition of a solution of NaBH4 (24.21 mg, 0.640 mmol) in MeOH (2 
mL), stirred for 30 minutes and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and 
the crude residue was dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl3 for 
1
H-NMR analysis. 
The crude mixture was purified on column chromatography (hexanes / EtOAc 40-80% and 10% DCM). All the reported 
yields are isolated yields. 
 
Method B (asymmetric protocol): 
To a solution of IPrAuNTf2 (13.84 mg, 0.016 mmol), 2,2’-bipyridine (4.99 mg, 0.032 mmol) and benzoic acid (3.90 mg, 
0.032 mmol) in Toluene (0.5 ml) in a dried Schlenk tube, was sequentially added a solution of the corresponding 
aldehyde 2 (0.320 mmol) and chiral organocatalyst (0.032 mmol) in Toluene (0.5 ml) and another solution of the 
corresponding allenamide 1 (0.160 mmol) in Toluene (0.5 ml; dropwise adition). The mixture was stirred under Argon 
atmospher at 60 ºC until all the allenamide was consumed (the progress of the reaction was easily monitored by tlc) 
and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed and the crude residue was 
dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl3 for 
1
H-NMR analysis. The crude mixture 
was then purified on column chromatography (hexanes/EtOAc 10-40%). All the reported yields are isolated yields. 
 
Method B´(asymmetric protocol followed by in situ reduction with NaBH4): 
Same conditions than Method B but once the allenamide was consumed (the progress of the reaction was easily 
monitored by tlc) the reaction was quenched with the addition of a solution of NaBH4 (24.21 mg, 0.640 mmol) in MeOH 
(2 mL), stirred for 30 minutes and filtered through a short pad of florisil, eluting with EtOAc. The solvent was removed 
and the crude residue was dissolved in 0.6 ml of a 1,3,5-trimethoxybenzene 0.0887 M solution in CDCl3 for 
1
H-NMR 
analysis. The crude mixture was purified on column chromatography (hexanes/EtOAc 40-80% and 10% DCM). All the 




(E)-2-Methyl-5-(2-oxooxazolidin-3-yl)-2-phenylpent-4-enal (3aa)  
Method A: 83% yield. Method B: 66% yield (72% ee). 
1
H NMR (300 MHz, CDCl3) δ 9.51 (s, 1H), 
7.46 – 7.20 (m, 5H), 6.64 (d, J = 14.3 Hz, 1H), 4.50 (dt, J = 14.3, 7.6 Hz, 1H), 4.42 – 4.30 (m, 2H), 
3.63 – 3.47 (m, 2H), 2.64 (d, J = 7.6 Hz, 1H), 1.43 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 201.97 (CH), 
155.33 (C), 139.37 (C), 129.03 (CH), 127.55 (CH), 127.12 (CH), 126.67 (CH), 105.19 (CH), 62.18 
(CH2), 54.13 (C), 42.58 (CH2), 36.99 (CH2), 18.90 (CH3). LRMS (m/z, ESI): 282.11 (M+Na)
+
, 258.11, 201.04, 126.05. HRMS 
Calculated for C15H17NNaO3: 282.1101, found 282.1103. HPLC Enantioselectivity was determined by chiral HPLC analysis 
on Chiralpak OZ-H at rt, (Hexane : iPrOH = 90:10, 1 ml/min). 
Racemic sample: 
 
Table 3, entry 5; ee = 72%:  
 
Table 3, entry 6; ee = 75%:  
 
Table 3, entry 7; ee = 81%:  
 




Table 3, entry 9: ee = 81% : 
 
Table 3, entry 10; ee = 83%: 
 
(E)-2-(4-Methoxyphenyl)-2-methyl-5-(2-oxooxazolidin-3-yl)pent-4-enal (3ab) 
Method A: 75% yield. Method B: 40% yield (68% ee). 
1
H NMR (300 MHz, CDCl3) δ 9.46 (s, 1H), 
7.15 (d, J = 8.9 Hz, 2H), 6.91 (d, J = 8.9 Hz, 2H), 6.65 (d, J = 14.3 Hz, 1H), 4.59 – 4.42 (m, 1H), 4.45 
– 4.29 (m, 2H), 3.81 (s, 3H), 3.64 – 3.50 (m, 2H), 2.62 (d, J = 6.7 Hz, 2H), 1.41 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ 201.93 (CH), 159.01 (C), 155.39 (C), 131.15 (C), 128.35 (CH), 126.66 (CH), 114.50 
(CH), 105.44 (CH), 62.21 (CH2), 55.42 (CH3), 53.48 (C), 42.67 (CH2), 37.03 (CH2), 19.02 (CH3). 
LRMS (m/z, ESI): 312.12 (M+Na)
+
, 185.09, 175.10, 159.08, 144.05, 126.05. HRMS Calculated for C16H19NNaO4: 312.1206, 
found 312.1210. HPLC Enantioselectivity was determined by chiral HPLC analysis on Chiralpak IA at rt, (Hexane : iPrOH = 
80:20, 1 ml/min). 
Racemic sample: 
 
Table 3, entry 11; ee = 68%: 
 
(E)-3-(4-(4-Fluorophenyl)-5-hydroxy-4-methylpent-1-en-1-yl)oxazolidin-2-one (3ac´) 
Method A´: 40% yield. 
1
H NMR (300 MHz, CDCl3) δ 7.37 – 7.27 (m, 2H), 7.03 (t, J = 8.8 Hz, 2H), 
6.65 (d, J = 14.3 Hz, 1H), 4.48 (ddd, J = 14.3, 8.1, 6.9 Hz, 1H), 4.42 – 4.30 (m, 2H), 3.72 (d, J = 
10.9 Hz, 1H), 3.63 – 3.47 (m, 3H), 2.61 – 2.47 (m, 1H), 2.34 (ddd, J = 14.1, 8.2, 1.1 Hz, 1H), 1.59 
(br, 1H), 1.31 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 161.49 (d, J = 245.6 Hz, C), 155.43 (C), 140.25 
S7 
 
(C), 128.39 (d, J = 7.8 Hz, CH), 126.20 (CH), 115.39 (d, J = 20.8 Hz, CH), 106.12 (CH), 71.69 (CH2), 62.19 (CH2), 43.34 (C), 
42.69 (CH2), 39.16 (CH2), 22.17 (CH3). LRMS (m/z, ESI): 302.11 (M+Na)
+
. 193.10, 175.09, 149.08. HRMS Calculated for 
C15H18FNNaO3: 302.1163, found 302.1169. 
(E)-2-Methyl-5-(2-oxooxazolidin-3-yl)-2-(5,6,7,8-tetrahydronaphthalen-2-yl)pent-4-enal (3ad) 
Method A: 47% yield. 
1
H NMR (300 MHz, CDCl3) δ 9.47 (s, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.95 (dd, 
J = 8.0, 2.1 Hz, 1H), 6.90 (s, 1H), 6.66 (d, J = 14.3 Hz, 1H), 4.56 (dt, J = 14.3, 7.6 Hz, 1H), 4.44 – 
4.32 (m, 2H), 3.66 – 3.49 (m, 2H), 2.80 – 2.70 (m, 4H), 2.63 (ddd, J = 7.3, 6.0, 1.2 Hz, 2H), 1.85 – 
1.74 (m, 4H), 1.40 (s, 3H). 
13
C NMR (75 MHz, CDCl3) δ 202.13 (CH), 155.39 (C), 137.89 (C), 136.67 
(C), 136.40 (C), 129.83 (CH), 127.87 (CH), 126.60 (CH), 124.17 (CH), 105.62 (CH), 62.22 (CH2), 
53.78 (CH), 42.71 (CH2), 36.92 (CH2), 30.46 (C), 29.70 (CH2), 29.09 (CH2), 23.22 (CH2), 18.99 (CH3). 
LRMS (m/z, ESI): 336.15 (M+Na)
+
, 209.13, 199.12, 149.05, 141.07. HRMS Calculated for C19H23NNaO3: 336.1570, found 
336.1575. 
(E)-3-(5-Hydroxy-4-phenylpent-1-en-1-yl)oxazolidin-2-one (3ae´) 
Method A´: 98% yield. Method B´: 99% yield (30% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.36 – 7.16 
(m, 5H), 6.64 (d, J = 14.3 Hz, 1H), 4.66 (dt, J = 14.8, 7.4 Hz, 1H), 4.36 (t, J = 8.3 Hz, 2H), 3.86 – 
3.67 (m, 2H), 3.56 (t, J = 8.7 Hz, 2H), 2.83 (dt, J = 13.2, 6.8 Hz, 1H), 2.51 (ddd, J = 14.3, 7.8, 6.5 
Hz, 1H), 2.47 – 2.30 (m, 1H), 1.58 (br s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 155.47 (C), 141.72 (C), 
128.81 (CH), 128.09 (CH), 127.01 (CH), 125.24 (CH), 108.57 (CH), 66.83 (CH2), 62.21 (CH2), 
49.24 (CH), 42.64 (CH2), 32.70 (CH2). LRMS (m/z, ESI): 270.10 (M+Na)
+
, 236.14, 230.11, 143.08. HRMS Calculated for 
C14H17NNaO3: 270.1101, found 270.1100. HPLC Enantioselectivity was determined by chiral HPLC analysis on Chiralpak 
IA3 at rt, (Hexane : iPrOH = 85:15, 1 ml/min). 
Racemic sample: 
 
Table 3, entry 14; ee = 30%: 
 
(E)-3-(5-Hydroxy-4-(4-methoxyphenyl)pent-1-en-1-yl)oxazolidin-2-one (3af´) 
Method A´: 99% yield. 
1
H NMR (300 MHz, CDCl3) δ 7.11 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.8 Hz, 
2H), 6.64 (d, J = 14.3 Hz, 1H), 4.65 (dt, J = 14.4, 7.4 Hz, 1H), 4.37 (t, J = 8.2 Hz, 2H), 3.79 (s, 3H), 
3.81 – 3.63 (m, 2H), 3.64 – 3.41 (m, 2H), 2.79 (p, J = 6.8 Hz, 1H), 2.56 – 2.39 (m, 1H), 2.43 – 
2.26 (m, 1H), 1.45 (br s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 158.64 (C), 155.45 (C), 133.52 (C), 
129.03 (CH), 125.23 (CH), 114.29 (CH), 108.63 (CH), 67.05 (CH2), 62.19 (CH2), 55.38 (CH3), 
48.45 (CH), 42.67 (CH2), 32.88 (CH2). LRMS (m/z, ESI): 300.12 (M+Na)
+
, 173.09, 158.08, 147.08, 




Method A´: 99% yield. 
1
H NMR (300 MHz, CDCl3) δ 7.19 – 7.10 (m, 2H), 7.05 – 6.96 (m, 2H), 
6.63 (d, J = 14.3 Hz, 1H), 4.62 (ddd, J = 14.5, 7.8, 6.9 Hz, 1H), 4.37 (t, J = 8.2 Hz, 2H), 3.85 – 3.66 
(m, 2H), 3.66 – 3.47 (m, 2H), 2.81 (dq, J = 8.4, 6.4 Hz, 1H), 2.50 (dddd, J = 14.2, 7.7, 6.3, 1.2 Hz, 
1H), 2.34 (dddd, J = 14.3, 8.4, 6.9, 1.4 Hz, 1H), 1.68 (br, 1H). 
13
C NMR (75 MHz, CDCl3) δ 161.70 
(d, J = 244.6 Hz, C), 155.33 (C), 137.34 (d, J = 3.5 Hz, C), 129.35 (d, J = 7.9 Hz, CH), 125.25 (CH), 
115.45 (d, J = 21.1 Hz, CH), 108.15 (CH), 66.62 (CH2), 62.09 (CH2), 48.35 (CH), 42.50 (CH2), 32.66 (CH2). LRMS (m/z, ESI): 
288.10 (M+Na)
+
., 279.09, 135.06, 109.04 HRMS Calculated for C14H16FNNaO3: 288.1006, found 288.1008.  
(E)-3-(5-Hydroxy-4-(p-tolyl)pent-1-en-1-yl)oxazolidin-2-one (3ah´) 
Method A´: 99% yield. Method B´: 96% yield (40% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.13 (d, J = 
8.5 Hz, 2H), 7.07 (d, J = 8.2 Hz, 2H), 6.63 (d, J = 14.3 Hz, 1H), 4.74 – 4.58 (m, 1H), 4.36 (t, J = 8.3 
Hz, 2H), 3.81 – 3.64 (m, 2H), 3.57 (td, J = 7.8, 1.9 Hz, 2H), 2.88 – 2.70 (m, 1H), 2.59 – 2.40 (m, 
1H), 2.44 – 2.32 (m, 1H), 2.32 (s, 3H), 1.62 (br, 1H). 
13
C NMR (75 MHz, CDCl3) δ 155.48 (C), 
138.54 (C), 136.51 (C), 129.50 (CH), 127.93 (CH), 125.12 (CH), 108.73 (CH), 66.89 (CH2), 62.20 
(CH2), 48.79 (CH), 42.65 (CH2), 32.74 (CH2), 21.12 (CH3). LRMS (m/z, ESI): 284.12 (M+Na)
+
, 175.11, 157.10, 142.07, 
131.08. HRMS Calculated for C15H19NNaO3: 284.1257, found 284.1257. HPLC Enantioselectivity was determined by 
chiral HPLC analysis on Chiralpak IA3 at rt, (Hexane : iPrOH = 85:15, 1 ml/min). 
Racemic sample: 
 
Table 3, entry 15; ee = 40%: 
 
(E)-3-(4-(3-Chlorophenyl)-5-hydroxypent-1-en-1-yl)oxazolidin-2-one (3ai´) 
Method A´: 99% yield. Method B´: 99% yield (44% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.29 – 7.14 
(m, 3H), 7.13 – 7.03 (m, 1H), 6.63 (d, J = 14.3 Hz, 1H), 4.62 (dt, J = 14.5, 7.3 Hz, 1H), 4.37 (t, J = 
8.4 Hz, 2H), 3.84 – 3.65 (m, 2H), 3.63 – 3.50 (m, 2H), 2.88 – 2.71 (m, 1H), 2.58 – 2.41 (m, 1H), 
2.43 – 2.26 (m, 1H), 1.87 (br, 1H). 
13
C NMR (75 MHz, CDCl3) δ 155.39 (C), 144.04 (C), 134.38 
(C), 129.89 (CH), 128.15 (CH), 126.99 (CH), 126.16 (CH), 125.34 (CH), 108.00 (CH), 66.26 (CH2), 
62.15 (CH2), 48.85 (CH), 42.52 (CH2), 32.43 (CH2). LRMS (m/z, ESI): 306.06, 304.07 (M+Na)
+
, 151.03, 125.01. HRMS 
Calculated for C14H16ClNNaO3: 304.0711, found 304.0712. HPLC Enantioselectivity was determined by chiral HPLC 







Table 3, entry 16; ee = 44%: 
 
(E)-2-Methyl-5-(2-oxopyrrolidin-1-yl)-2-phenylpent-4-enal (3ba) 
Method A: 52% yield. Method B: 52% yield (82% ee).
1
H NMR (500 MHz, CDCl3) δ 9.51 (s, 1H), 
7.40 – 7.35 (m, 2H), 7.31 – 7.27 (m, 1H), 7.23 (dd, J = 8.3, 1.3 Hz, 2H), 6.88 (d, J = 14.4 Hz, 1H), 
4.62 (dt, J = 14.7, 7.6 Hz, 1H), 3.39 – 3.33 (m, 2H), 2.66 (dd, J = 7.5, 1.2 Hz, 2H), 2.48 – 2.41 (m, 
2H), 2.09 – 1.99 (m, 2H), 1.43 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 202.12 (CH), 173.04 (C), 
139.57 (C), 129.04 (CH), 127.53 (CH), 127.17 (CH), 126.48 (CH), 106.22 (CH), 54.20 (C), 45.31 
(CH2), 37.30 (CH2), 31.29 (CH2), 19.01 (CH3), 17.44 (CH2). LRMS (m/z, ESI): 280.13 (M+Na)
+
, 230.13, 147.06, 124.07. 
HRMS Calculated for C16H19NNaO2: 280.1308, found 280.1311. HPLC Enantioselectivity was determined by chiral HPLC 
analysis on Chiralpak IA3 at rt, (Hexane : iPrOH = 85:15, 1 ml/min). 
Racemic sample 
 
Table 3, entry 12, ee = 82% 
 
(E)-N-(5-Hydroxy-4-methyl-4-phenylpent-1-en-1-yl)-4-methyl-N-phenylbenzenesulfonamide (3ca’) 
Method A´: 47% yield.  
1
H NMR (300 MHz, CDCl3) δ 7.42 (d, J = 8.3 Hz, 2H), 7.34 – 7.12 (m, 10H), 
6.89 – 6.70 (m, 3H), 4.20 (dt, J = 14.0, 7.8 Hz, 1H), 3.68 (d, J = 10.9 Hz, 1H), 3.51 (d, J = 10.9 Hz, 
1H), 2.44 (s, 3H), 2.31 (qdd, J = 13.8, 7.8, 1.2 Hz, 2H), 1.57 (br s, 1H), 1.20 (s, 3H). 
13
C NMR (75 
MHz, CDCl3) δ 144.53 (C), 143.80 (C), 137.03 (C), 136.00 (C), 131.13 (CH), 130.04 (CH), 129.65 
S10 
 
(CH), 129.40 (CH), 128.85 (CH), 128.53 (CH), 127.55 (CH), 126.68 (CH), 126.34 (CH), 108.35 (CH), 71.35 (CH2), 43.95 (C), 
39.27 (CH2), 21.81 (CH3), 21.75 (CH3). LRMS (m/z, ESI): 422.17 (M+H)
+
, 266.14, 157.07. HRMS Calculated for C25H28NO3S: 
422.1784, found 422.1786. 
(E)-N-Benzyl-N-(5-hydroxy-4-methyl-4-phenylpent-1-en-1-yl)-4-methylbenzenesulfonamide (3da´) 
Method A´: 51% yield. Method B´: 50% yield (80% ee). 
1
H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 
8.2 Hz, 2H), 7.33 – 7.24 (m, 7H), 7.24 – 7.17 (m, 1H), 7.17 – 7.06 (m, 4H), 6.59 (d, J = 14.2 Hz, 
1H), 4.48 – 4.38 (m, 2H), 4.31 (d, J = 15.6 Hz, 1H), 3.55 (d, J = 10.9 Hz, 1H), 3.41 (d, J = 10.9 Hz, 
1H), 2.45 (s, 3H), 2.36 (ddd, J = 13.9, 7.1, 1.2 Hz, 1H), 2.20 (ddd, J = 13.9, 8.1, 1.0 Hz, 1H), 1.13 
(br s, 1H), 1.05 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ 144.30 (C), 143.80 (C), 136.04 (C), 135.54 (C), 129.90 (CH), 128.64 
(CH), 128.51 (CH), 127.47 (CH), 127.41 (CH), 127.15 (CH), 127.04 (CH), 126.64 (CH), 126.27 (CH), 109.50 (CH), 71.26 
(CH2), 49.45 (CH2), 43.64 (C), 39.75 (CH2), 21.70 (CH3), 21.59 (CH3). LRMS (m/z, ESI): 458.17 (M+Na)
+
, 168.05. HRMS 
Calculated for C26H29NNaO3S: 458.1760, found 458.1768. HPLC Enantioselectivity was determined by chiral HPLC 
analysis on Chiralpak OZ-H at rt, (Hexane : iPrOH = 90:10, 0.5 ml/min). 
Racemic sample 
 
Table 3, entry 13; ee = 80%: 
 
(E)-N-Benzyl-N-(5-hydroxy-4-phenylpent-1-en-1-yl)-4-methylbenzenesulfonamide (3de´) 
Method A: 99% yield. Method B: 99% yield (70% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 
8.3 Hz, 2H), 7.29 – 7.21 (m, 8H), 7.19 – 7.14 (m, 2H), 6.99 – 6.92 (m, 2H), 6.60 (d, J = 14.1 Hz, 
1H), 4.55 (dt, J = 14.4, 7.3 Hz, 1H), 4.37 (d, J = 3.2 Hz, 2H), 3.58 (s, 2H), 2.69 – 2.56 (m, 1H), 2.43 
(s, 3H), 2.39 – 2.28 (m, 1H), 2.30 – 2.13 (m, 1H), 1.26 (br, 1H). 
13
C NMR (75 MHz, CDCl3) δ 
143.75 (C), 141.52 (C), 136.07 (C), 135.62 (C), 129.89 (CH), 128.70 (CH), 128.63 (CH), 128.07 (CH), 127.46 (CH), 127.08 
(CH), 127.00 (CH), 126.79 (CH), 110.76 (CH), 66.49 (CH2), 49.50 (CH2), 48.96 (CH), 33.31 (CH2), 21.68 (CH3). LRMS (m/z, 
ESI): 422.17 (M+H)
+
, 300.10, 279.08. HRMS Calculated for C25H28NO3S: 422.1784, found 422.1787. HPLC 








Table 3, entry 17, ee = 70% 
 
(E)-N-benzyl-N-(5-hydroxy-4-(4-methoxyphenyl)pent-1-en-1-yl)-4-methylbenzenesulfonamide (3df´) 
Method A´: 99% yield. 
1
H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 8.2 Hz, 2H), 7.30 – 7.25 (m, 5H), 
7.19 (d, J = 6.0 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 6.84 – 6.78 (m, 2H), 6.61 (d, J = 14.5 Hz, 1H), 4.57 
(dt, J = 14.4, 7.3 Hz, 1H), 4.39 (q, J = 15.8 Hz, 2H), 3.82 (s, 3H), 3.57 (dd, J = 6.9, 2.6 Hz, 2H), 2.66 
– 2.55 (m, 1H), 2.44 (s, 3H), 2.40 – 2.28 (m, 1H), 2.20 (dt, J = 15.2, 8.0 Hz, 1H), 1.25 (d, J = 6.9 Hz, 
1H). 
13
C NMR (126 MHz, CDCl3) δ 158.36 (C), 143.73 (C), 136.01 (C), 135.61 (C), 133.36 (C), 
129.85, 128.97 (CH), 128.58 (CH), 127.41 (CH), 127.05 (CH), 126.99 (CH), 126.95 (CH), 114.08 (CH), 110.83 (CH), 66.61 





353.26  HRMS Calculated for C26H30NO4S: 452.1890, found 452.1892. 
(E)-N-benzyl-N-(4-(4-fluorophenyl)-5-hydroxypent-1-en-1-yl)-4-methylbenzenesulfonamide (3dg´) 
Method A´: 99% yield. Method B´: 99% yield (48% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.55 (d, J = 
8.3 Hz, 2H), 7.34 – 7.18 (m, 5H), 7.18 – 7.10 (m, 2H), 7.03 – 6.80 (m, 4H), 6.57 (d, J = 14.2 Hz, 
1H), 4.57 – 4.41 (m, 1H), 4.45 – 4.27 (m, 2H), 3.57 (dd, J = 6.8, 1.2 Hz, 2H), 2.69 – 2.51 (m, 1H), 
2.43 (s, 3H), 2.40 – 2.30 (m, 1H), 2.30 – 2.07 (m, 1H), 1.26 (s, 1H).
13
C NMR (75 MHz, CDCl3) δ 
161.67 (d, J = 244.4 Hz, C), 143.87 (C), 137.15 (d, J = 3.3 Hz, C), 136.03 (C), 135.58 (C), 129.90 
(CH), 129.45 (d, J = 7.9 Hz, CH), 128.63 (CH), 127.48 (CH), 127.20 (CH), 127.00 (CH), 126.96 (CH), 115.42 (d, J = 21.0 Hz, 





, 420.14, 300.10. HRMS Calculated for C25H27FNO3S: 440.1690, found 440.1680. HPLC Enantioselectivity 







Table 3, entry 18: ee = 48% 
 
(E)-N-benzyl-N-(5-hydroxy-4-(p-tolyl)pent-1-en-1-yl)-4-methylbenzenesulfonamide (3dh´) 
Method A’: 99% yield. Method B’: 99% yield (72% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 
8.3 Hz, 2H), 7.31 – 7.22 (m, 5H), 7.20 – 7.13 (m, 2H), 7.06 (d, J = 7.6 Hz, 2H), 6.85 (d, J = 8.0 Hz, 
2H), 6.60 (d, J = 14.2 Hz, 1H), 4.57 (dt, J = 14.5, 7.4 Hz, 1H), 4.38 (d, J = 3.0 Hz, 2H), 3.56 (d, J = 
6.7 Hz, 2H), 2.68 – 2.49 (m, 1H), 2.43 (s, 3H), 2.33 (s, 3H), 2.41 – 2.26 (m, 1H), 2.32 – 2.12 (m, 
1H), 1.27 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 143.72 (C), 138.37 (C), 136.23 (C), 136.06 (C), 
135.61 (C), 129.85 (CH), 129.39 (CH), 128.59 (CH), 127.92 (CH), 127.44 (CH), 127.09 (CH), 127.01 (CH), 110.98 (CH), 







300.10. HRMS Calculated for C26H29NNaO3S: 458.1760, found 458.1766. HPLC Enantioselectivity was 
determined by chiral HPLC analysis on Chiralpak IA3 at rt, (Hexane : iPrOH = 95:5, 1 ml/min). 
Racemic sample: 
 
Table 3, entry 19: ee = 72% 
 
(E)-N-Benzyl-N-(4-(3-chlorophenyl)-5-hydroxypent-1-en-1-yl)-4-methylbenzenesulfonamide (3di´) 
Method A’: 99% yield. Method B’: 99% yield (67% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.56 (d, J = 
8.3 Hz, 2H), 7.32 – 7.11 (m, 9H), 6.99 (s, 1H), 6.82 (dt, J = 6.3, 1.9 Hz, 1H), 6.59 (d, J = 14.2 Hz, 
1H), 4.58 – 4.42 (m, 1H), 4.43 – 4.28 (m, 2H), 3.56 (d, J = 6.6 Hz, 2H), 2.67 – 2.51 (m, 1H), 2.43 (s, 
3H), 2.39 – 2.27 (m, 1H), 2.26 – 2.12 (m, 1H), 1.29 (s, 1H). 
13
C NMR (75 MHz, CDCl3) δ 143.87 (C), 
136.01 (C), 135.50 (C), 134.44 (C), 129.93 (CH), 128.67 (CH), 128.26 (CH), 127.52 (CH), 127.35 (CH), 127.01 (CH), 126.97 





, 311.03, 300.10. HRMS Calculated for C25H26ClNNaO3S: 478.1214, found 478.1216. HPLC 





Table 3, entry 20: ee = 67% 
 
(E)-3-(4-Benzyl-5-hydroxypent-1-en-1-yl)oxazolidin-2-one (3aj´) 
Reaction carried out in acetonitrile under otherwise identical conditions of Method B’: 45% 
yield (34% ee). 
1
H NMR (300 MHz, CDCl3) δ 7.36 – 7.12 (m, 5H), 6.67 (d, J = 14.3 Hz, 1H), 4.84 – 
4.67 (m, 1H), 4.42 (dd, J = 8.5, 7.7 Hz, 2H), 3.64 (td, J = 7.7, 1.7 Hz, 2H), 3.59 – 3.52 (m, 2H), 
2.64 (qd, J = 13.7, 7.2 Hz, 2H), 2.27 – 2.01 (m, 2H), 1.99 – 1.79 (m, 1H), 1.25 (s, 1H). 
13
C NMR 
(75 MHz, CDCl3) δ 155.48 (C), 140.55 (C), 129.28 (CH), 128.54 (CH), 126.16 (CH), 125.42 (CH), 
108.85 (CH), 64.75 (CH2), 62.25 (CH2), 43.39 (CH), 42.74 (CH2), 37.54 (CH2), 31.53 (CH2). LRMS (m/z, ESI): 284.12 
(M+Na)
+
, 273.08, 236.14. HRMS Calculated for C15H19NNaO3: 284.1257, found 284.1258. HPLC Enantioselectivity was 
determined by chiral HPLC analysis on Chiralpak IA3 at rt, (Hexane : iPrOH = 85:15, 1 ml/min). 
Racemic sample 
 




Additional data obtained in the optimization of the racemic alkylation of aldehydes 




Entry gold catalyst ( X mol %) t (h) yield (%) 
1 none 46 0 
2 Au1 (10) 1 30 
3 Au2 (10) 3.5 88 
4 Au3 (10) 3 25 
5 Ph3PAuNTf2 (5) 1.5 43 
6 Ph3PAuNTf2 (10) 0.3 83 
7 Ph3PAuCl/AgSbF6 (10) 18 23 
8 XPhosAuNTf2 (10) 0.5 5 
9 JohnPhosAuNTf2 (10) 0.5 6 
10 tBuXPhosAuNTf2 (10) 0.5 5 
11 RuPhosAuNTf2 (10) 1 10 
12 SPhosAuNTf2 (10) 0.7 12 
13 (tBu)3PAuNTf2 (10) 0.5 14 
14 (pCF3C6H4)3PAuNTf2 (10) 0.7 73 
15 Ph3PAu(TA)OTf (10) 6 63 
16 IMesAuNTf2 (10) 0.5 63 
17 IPrAuNTf2 (10) 3 68 
a All reactions were carried out using conditions described in Method A. Yields determined by 
Internal Standard [1,3,5-(MeO)3C6H3] unless otherwise noted. 
 
Table S2 Influence of the solvent. 
 
Entry Solvent t (h) yield (%) 
1 Toluene 0.3 83 
2 Tetrahydrofuran 0.5 10 
3 1,4-Dioxane 0.5 15 
4 Acetonitrile 0.3 39 
All reactions were carried out using conditions described in Method A. Yields determined by 
Internal Standard [1,3,5-(MeO)3C6H3] unless otherwise noted. 
S15 
 
Table S3 Influence of the acid. 
 
Entry Acid t (h) yield (%) 
1 none 0.5 25 
2 4a 0.3 83 
3 4b 0.5 41 
4 4c 0.5 39 
5 4d 0.3 43 
6 4e 1 30 
All reactions were carried out using conditions described in Method A. Yields determined by 
Internal Standard [1,3,5-(MeO)3C6H3] unless otherwise noted 
 
Additional data obtained in the optimization of the asymmetric alkylation of aldehydes 
Table S4. Screening of MacMillan Organocatalysts 
 
Entry Organocatalyst (C) t (h) yield (%) ee (%) 
1
a
 C1 1 13 39 
2 C1b 2 <5 - 










 C1e 2 -
b
 - 
All reactions were carried out using conditions described in Method B. Yields determined by Internal Standard [1,3,5-
(MeO)3C6H3] unless otherwise noted. 





Table S5  Screening of chiral Organocatalyst C4 with different gold catalysts 
 
Entry gold catalyst  Organocatalyst ( Xmol%) t (h) yield (%) ee (%) 
1 Ph3PAuNTf2  C4 (30) 0.5 68 59 
2 (pCF3C6H4)3PAuNTf2  C4 (30) 0.7 71 48 
3 Ph3PAu(TA)OTf  C4 (30) 1 53 67 
4 IMesAuNTf2  C4 (30) 2.5 20 58 
5 IPrAuNTf2  C4 (20) 0.5 66 72 
All reactions were carried out using conditions described in Method B. Yields determined by Internal Standard [1,3,5-
(MeO)3C6H3] unless otherwise noted.  
Table S6 Influence of the structure of the Prolinol.  
 
Entry organocatalyst t (h) yield (%) ee (%) 
1 C4 0.5 66 72 
2 C5 0.5 30 81 
3 C6 0.7 25 81 
4 C7 0.7 23 83 
5 C8 1 35 61 
6 C9 0.7 56 0 
7 C10 0.7 15 44 
8 C11 4 24 73 
9 C12 0.7 26 65 
10 C13 1 32 35 
11 C14 0.7 33 48 
12 C15 1 28 47 






Table S7. Influence of the additive. 
 
Entry additive t (h) yield (%) ee (%) 
1 none 0.3 37 76 
2 Bpy (4a) 0.5 66 72 
3 4b 1 33 80 
4 4c 0.5 55 73 
5 4d 0.5 50 74 
6 4e 2 66 70 
7 4f 2 20 50 
All reactions were carried out using conditions described in Method B. Yields determined by 
Internal Standard [1,3,5-(MeO)3C6H3] unless otherwise noted. 
 
Table S8. Influence of the acid.  
 
Entry Acid (5) t (h) yield (%) ee (%) 
1 5a 0.5 66 72 
2 5b 0.3 53 74 
3 5c 0.5 50 73 
4 5d 0.5 42 76 
5 5e 0.7 67 69 
All reactions were carried out using conditions described in Method B. Yields determined by Internal 
Standard [1,3,5-(MeO)3C6H3] unless otherwise noted  
 








NMR and ESI-MS experiments 
 
1. Ph3PAuNTf2 (d8-toluene complex, 2:1) 
ESI-MS : M+= 559.14,     31P-NMR: 31.12 ppm 
 
2. Ph3PAu(Bpy)NTf2 ( Prepared by mixing Bpy and Ph3PAuNTf2 ( ratio 1:1) 
ESI-MS : M+= 615.17,      31P-NMR: 31.52 ppm 








3. Ph3PAu(C4)NTf2  ( Prepared by mixing C4 and Ph3PAuNTf2 ( ratio 1:1) 
ESI-MS :M+ = 784.43      31P-NMR: 30.56 ppm 
    
Ph3PAu(C4)NTf2  + Bpy (2 equiv) 



















Ph3PAu(Bpy)NTf2 + C4 ( 1 equiv) 
   
Ph3PAu(C4)NTf2  + Bpy + Phenylacetaldehyde 
 
 
Ph
3
PAu(Bpy)NTf
2
 
Ph
3
PAu(C4)NTf
2 
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